688621.SSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (6 5月 2024 @ 11:30):

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of chemical drugs and peptide drugs in China...

Stats
本日の出来高	1.01M
平均出来高	1.09M
時価総額	6.60B
EPS	CNY0 ( 2023-10-30 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	33.32
ATR14	CNY0.165 (0.28%)

ボリューム相関

長: -0.11 (neutral)

短: 0.07 (neutral)

Signal:(63.218) Neutral

Beijing Sun-Novo 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Beijing Sun-Novo 相関 - 通貨/商品

0.10
( neutral )

-0.79
( moderate negative )

0.00
( neutral )

0.91
( very strong )

0.05
( neutral )

Beijing Sun-Novo 財務諸表

Annual	2023
収益:	CNY932.12M
総利益:	CNY528.35M (56.68 %)
EPS:	CNY1.650

FY	2023
収益:	CNY932.12M
総利益:	CNY528.35M (56.68 %)
EPS:	CNY1.650

FY	2022
収益:	CNY676.61M
総利益:	CNY375.46M (55.49 %)
EPS:	CNY1.390

FY	2021
収益:	CNY493.65M
総利益:	CNY263.68M (53.41 %)
EPS:	CNY1.764

Financial Reports:

No articles found.

Beijing Sun-Novo

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of chemical drugs and peptide drugs in China. The company offers small molecule chemical generic drugs; peptide products; and drugs for indications, such as impetigo, acne, renal anemia, chronic kidney disease dialysis patient hyper parathyroid hormone, analgesia, and other symptoms. It also provides packaging material compatibility test, impurity research, extract research, migration research, safety evaluation, and other research services; consistency evaluation services; clinical research services; registration consulting and agency services; and range of pharmacokinetics-pharmacodynamics and GLP bioanalysis services, including pharmacokinetic bioanalysis, immunogenic biology analysis, pharmacodynamics, and biomarker bioanalysis services. The company was founded in 2009 and is based in Beijing, China.